Gene therapy aims to restore hearing in deaf children
NCT ID NCT07288580
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a gene therapy called EHT102 for children with congenital hearing loss caused by mutations in the OTOF gene. Up to 30 children will receive a single injection in one ear to see if it safely improves hearing. The study is early-stage, focusing on safety and whether hearing thresholds can be lowered to 70 decibels or better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EHT102 injection (gene therapy)
- What this could lead to
- If successful, this could restore hearing in children born deaf due to OTOF mutations, potentially reducing the need for hearing aids or cochlear implants.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply to all. Gene therapy carries risks like immune reactions or incomplete hearing restoration.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT OF CONGENITAL HEARING LOSS SECONDARY TO BIALLELIC MUTATIONS OF THE OTOFERLIN GENE (OTOF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye & ENT Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China